A New Drug Just Nearly Doubled Survival for Pancreatic Cancer Patients — Dallas’s UT Southwestern Is at the Forefront of What Researchers Are Calling a Historic Breakthrough

The drug daraxonrasib nearly doubled overall survival in metastatic pancreatic cancer in a Phase 3 trial presented at ASCO 2026. UT Southwestern Medical Center is among leading institutions involved in KRAS research.